Overall, the in vitro efficacy of HIF2α-CD27 PAMs in downregulating multiple oncogenic mechanisms and their clinical potential for ccRCC gene therapy are provided. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.